Arecoline via Miniosmotic Pump Improves AF64A-Impaired Radial Maze Performance in Rats: A Possible Model of Alzheimer's Disease

Male Sprague-Dawley rats, preoperatively trained in a 1-h delay non-match-to-position radial maze task, received bilateral stereotaxic injections of a selective cholinotoxin, ethylcholine aziridinium ion (AF64A: 3 nmol/3 microliters/lateral ventricle). Animals treated with AF64A made significantly more total postdelay errors than vehicle controls. Sustained delivery, via miniosmotic pumps, of arecoline (0.1, 0.3, 1, 3, 10, or 30 mg/kg/day sc for 14 days) attenuated the AF64A-induced cognitive impairment in a dose-dependent manner, producing an inverted U-shaped dose-response function which was optimal at 1.0 mg/kg/day. Following these studies, choline acetyltransferase activity was significantly reduced in hippocampi extracted from the AF64A-treated rats, indicating successful cholinotoxicity. This paradigm may be useful as a possible screen for potential Alzheimer's disease therapeutic agents. This conclusion is supported by published reports of beneficial arecoline effects observed following 2-week intravenous infusions in patients with Alzheimer's disease (Soncrant, Raffaele, Asthana, Berardi, Morris, & Haxby, 1993).

[1]  N. Greig,et al.  Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease , 1996, Clinical pharmacology and therapeutics.

[2]  B. Costall,et al.  Acute and chronic arecoline: Effects on a scopolamine-induced deficit in complex maze learning , 1996, Pharmacology Biochemistry and Behavior.

[3]  D. Gurwitz,et al.  M1 Agonists for the Treatment of Alzheimer's Disease. , 1996, Annals of the New York Academy of Sciences.

[4]  Yifan Han,et al.  Huperzine A Ameliorates the Spatial Working Memory Impairments Induced by AF64A , 1995 .

[5]  G. Celesia,et al.  Regional alterations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease. , 1995, Journal of neuropathology and experimental neurology.

[6]  S. Corkin,et al.  Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. , 1995, Archives of neurology.

[7]  R. Powers,et al.  Impaired phosphoinositide hydrolysis in Alzheimer's disease brain , 1994, Neurobiology of Aging.

[8]  P. Govitrapong,et al.  Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E , 1993, Neurochemistry International.

[9]  I. Hanin,et al.  Reversible cholinergic changes induced by AF64A in rat hippocampus and possible septal compensatory effect , 1992, Neuropharmacology.

[10]  E. Bronzetti,et al.  Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. , 1992, Drugs under experimental and clinical research.

[11]  J. Coyle,et al.  The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. , 1991, Mayo Clinic proceedings.

[12]  V. Luine,et al.  Spatial memory deficits in aged rats: contributions of the cholinergic system assessed by ChAT , 1990, Brain Research.

[13]  T. J. Walsh,et al.  Hemicholinium-3 prevents the working memory impairments and the cholinergic hypofunction induced by ethylcholine aziridinium ion (AF64A) , 1989, Brain Research.

[14]  R. Quirion,et al.  Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. , 1989, Trends in pharmacological sciences.

[15]  A. Fisher,et al.  (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats , 1989, Neuroscience Letters.

[16]  J. Coyle,et al.  Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. , 1989, The Journal of pharmacology and experimental therapeutics.

[17]  Y. Iga,et al.  Beneficial effects of FKS-508 (AF102B), a selective M1 agonist, on the impaired working memory in AF64A-treated rats. , 1989, Japanese journal of pharmacology.

[18]  T. J. Walsh,et al.  AF64A-induced working memory impairment: behavioral, neurochemical and histological correlates , 1988, Brain Research.

[19]  I. Hanin,et al.  Time course of ethylcholine aziridinium ion (AF64A)-induced cholinotoxicity in vivo , 1987, Neuropharmacology.

[20]  C. H. Vanderwolf,et al.  Hippocampal electrical activity in relation to behavior following ethylcholine aziridinium ion (AF64A) treatment , 1987, Pharmacology Biochemistry and Behavior.

[21]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[22]  D. Olton,et al.  Cholinergic function and memory: Extensive inhibition of choline acetyltransferase fails to impair radial maze performance in rats , 1986, Pharmacology Biochemistry and Behavior.

[23]  D. McKeag,et al.  Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices , 1985, Neuropharmacology.

[24]  T. J. Walsh,et al.  AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat , 1984, Brain Research.

[25]  Olton Ds.  The use of animal models to evaluate the effects of neurotoxins on cognitive processes. , 1983 .

[26]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.